Liraglutide: Uses, Mechanism, and Side Effects

Anyone managing type 2 diabetes wants to know how a medication works and what side effects to expect. Liraglutide is a widely studied injectable drug with decades of clinical trial data behind it.

Key takeaways

• Liraglutide is a GLP-1 receptor agonist used alongside diet and exercise to improve glycemic control.
• It is approved for adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.
• The label carries a boxed warning.
• Liraglutide has been studied in 543 registered clinical trials, including phase 3 trials in combination with other diabetes medications.
• The most commonly reported reactions in adverse event reports are gastrointestinal, led by nausea, vomiting, and diarrhoea.

What Liraglutide Is

Liraglutide is a GLP-1 receptor agonist, a class of drugs that mimics a hormone the body naturally produces after eating. It shares 97% of its amino acid sequence with the body's own GLP-1 hormone. Liraglutide activates the GLP-1 receptor on pancreatic beta cells, raising a signaling molecule called cyclic AMP that leads to insulin release. This action helps regulate blood sugar in response to food intake.

What Liraglutide Is Approved For

Liraglutide injection is approved as an adjunct to diet and exercise to improve glycemic control in adults and children aged 10 years and older with type 2 diabetes mellitus. It is marketed under the brand name Liraglutide. The label advises against combining it with other liraglutide-containing products. The prescribing information for liraglutide includes a boxed warning.

What the Evidence Shows

Liraglutide has been evaluated across 543 registered clinical trials. One completed phase 3 trial compared liraglutide combined with metformin against metformin alone and against a glimepiride and metformin combination. Another completed phase 3 trial examined individualized approaches to obesity pharmacotherapy, reflecting the broader research interest in this drug class beyond its approved diabetes indication.

Reported Side Effects

Adverse event reports for liraglutide are dominated by gastrointestinal symptoms: nausea (7,293 reports), vomiting (3,600), and diarrhoea (3,461). Changes in blood glucose, appetite, and body weight are also frequently reported, along with headache. Pancreatitis appears among the more serious reported reactions, with 2,356 reports. These figures reflect the number of reports submitted to a surveillance database, not confirmed incidence rates or proof that liraglutide caused the reaction.